Leading pharma major, Zydus Cadila has said that it has received the final approval from the USFDA to market Tamoxifen Citrate Tablets USP in the strengths of 10 mg (base) and 20 mg (base). “The drug is indicated to treat breast cancer in women and men and to reduce the incidence of breast cancer in women at high risk for breast cancer. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad,” the company said in a filing to the Bombay Stock Exchange.
The group now has more than 165 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04. Zydus Cadila is a fully integrated, global healthcare provider, with strengths all along the pharmaceutical value chain. With a core competence in the field of healthcare, Zydus Cadila provides total healthcare solutions ranging from formulations, active pharmaceutical ingredients and animal healthcare products to wellness products. Meanwhile, shares of the company were trading at Rs 496 apiece, up 0.94 per cent from the previous close at 10:12 hours on BSE.
